1 Min Read
March 22 (Reuters) - Knight Therapeutics Inc
* Says U.S. Commercialization partner, profounda inc has launched Impavido (miltefosine) in united states Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.